The United States Patent and Trademark Office (USPTO) has issued patent US12583839B2, granting exclusive rights to ADLAI NORTYE BIOPHARMA CO., LTD. for a novel PD-L1 antagonist compound. The patent, which includes a compound of Formula (I), a pharmaceutical composition thereof, and a method for treating immune-related disorders, was filed on December 22, 2020, and granted on March 24, 2026. This grant signifies a new intellectual property asset for the assignee in the field of immunology and drug development.

This patent grant primarily impacts the assignee by providing market exclusivity for the patented compound. For other entities in the pharmaceutical and biotechnology sectors, this represents a new patent to consider in their freedom-to-operate analyses and competitive intelligence. While this is a patent grant and not a regulatory rule with direct compliance obligations for other companies, it is crucial for R&D, legal, and business development teams to be aware of this new intellectual property to avoid potential infringement claims and to inform their own drug development strategies.